COCP

Business Context and Reporting Period

Cocrystal Pharma, Inc. filed this Form 8-K on March 3, 2015, to report a Special Meeting of Shareholders held on the same date. The primary purpose of the meeting was to approve an amendment to the Company's Certificate of Incorporation.

Key Financial Metrics

This filing is a current report regarding corporate governance and capital structure changes. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data.

Material Changes

• Authorized Common Stock: Increased from 200,000,000 to 800,000,000 shares.
• Preferred Stock Conversion: Upon filing the amendment, all outstanding Series A and Series B Preferred Stock were automatically converted into common stock without further action by holders.
• Conversion Details:
  • Series A converted into 340,760,802 shares of common stock.
  • Series B converted into 205,083,086 shares of common stock.
• Post-Conversion Status: No shares of Series A or Series B Preferred Stock remain outstanding.

Shareholder Vote Results

Shareholders approved the amendment to increase authorized common stock. The proposal required affirmative votes from common stockholders and preferred stockholders voting on an as-converted basis.

Outlook, Risks, and Management Commentary

The filing contains no management commentary regarding future outlook, risks, contingencies, or unusual items. The document strictly reports the procedural completion of the stock amendment and conversion.

Investor Verification Checklist

• Verify the total number of outstanding common shares post-conversion (pre-existing common + converted Series A + converted Series B).
• Confirm the dilution impact on existing common shareholders resulting from the conversion of preferred shares.
• Review the amended Certificate of Incorporation (Exhibit 3.1) for any other changes to corporate bylaws or rights.
• Check subsequent filings for the Company's cash position, as the filing does not provide liquidity data.